NCT00894894View on ClinicalTrials.gov

Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Solid Tumors
Interventions
DRUG

MP-470

escalating daily doses of amuvatinib

DRUG

amuvatinib (MP-470)

escalating doses of daily amuvatinib

Trial Locations (2)

78229

So. Texas Accelerated Research Therapeutics-START, San Antonio

85258

Translation Genomics Research Institute (TGen)/Scottsdale Clin.Researc, Scottsdale

Sponsors
All Listed Sponsors
lead

Astex Pharmaceuticals, Inc.

INDUSTRY